Literature DB >> 18820704

Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells.

T R Wilson1, M McEwan, K McLaughlin, C Le Clorennec, W L Allen, D A Fennell, P G Johnston, D B Longley.   

Abstract

Death receptors can directly (type I cells) or indirectly induce apoptosis by activating mitochondrial-regulated apoptosis (type II cells). The level of caspase 8 activation is thought to determine whether a cell is type I or II, with type II cells less efficient at activating this caspase following death receptor activation. FLICE-inhibitory protein (FLIP) blocks death receptor-mediated apoptosis by inhibiting caspase 8 activation; therefore, we assessed whether silencing FLIP could convert type II cells into type I. FLIP silencing-induced caspase 8 activation in Bax wild-type and null HCT116 colorectal cancer cells; however, complete caspase 3 processing and apoptosis were only observed in Bax wild-type cells. Bax-null cells were also more resistant to chemotherapy and tumor necrosis factor-related apoptosis inducing ligand and, unlike the Bax wild-type cells, were not sensitized to these agents by FLIP silencing. Further analyses indicated that release of second mitochondrial activator of caspases from mitochondria and subsequent inhibition of X-linked inhibitor of apoptosis protein (XIAP) was required to induce full caspase 3 processing and apoptosis following FLIP silencing. These results indicate that silencing FLIP does not necessarily bypass the requirement for mitochondrial involvement in type II cells. Furthermore, targeting FLIP and XIAP may represent a therapeutic strategy for the treatment of colorectal tumors with defects in mitochondrial-regulated apoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820704     DOI: 10.1038/onc.2008.366

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

Review 1.  Fas death receptor signalling: roles of Bid and XIAP.

Authors:  T Kaufmann; A Strasser; P J Jost
Journal:  Cell Death Differ       Date:  2011-09-30       Impact factor: 15.828

2.  S-nitrosylation of FLICE inhibitory protein determines its interaction with RIP1 and activation of NF-κB.

Authors:  Siera Jo Talbott; Sudjit Luanpitpong; Christian Stehlik; Neelam Azad; Anand Krishnan V Iyer; Liying Wang; Yon Rojanasakul
Journal:  Cell Cycle       Date:  2014-04-24       Impact factor: 4.534

3.  Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin.

Authors:  Tanvi S Jani; Jennifer DeVecchio; Tapati Mazumdar; Akwasi Agyeman; Janet A Houghton
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

4.  Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.

Authors:  M A Laussmann; E Passante; H Düssmann; J A Rauen; M L Würstle; M E Delgado; M Devocelle; J H M Prehn; M Rehm
Journal:  Cell Death Differ       Date:  2011-04-01       Impact factor: 15.828

5.  Cellular FLICE-like Inhibitory Protein (c-FLIP) and PS1-associated Protein (PSAP) Mediate Presenilin 1-induced γ-Secretase-dependent and -independent Apoptosis, Respectively.

Authors:  Linlin Zeng; Chen Hu; Fuqiang Zhang; Daniel C Xu; Mei-Zhen Cui; Xuemin Xu
Journal:  J Biol Chem       Date:  2015-05-29       Impact factor: 5.157

6.  The caspase-8 dimerization/dissociation balance is a highly potent regulator of caspase-8, -3, -6 signaling.

Authors:  Maximilian L Würstle; Maike A Laussmann; Markus Rehm
Journal:  J Biol Chem       Date:  2010-08-11       Impact factor: 5.157

7.  A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.

Authors:  Wendy L Allen; Leanne Stevenson; Vicky M Coyle; Puthen V Jithesh; Irina Proutski; Gail Carson; Michael A Gordon; Heinz-Josef D Lenz; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Mol Cancer Ther       Date:  2011-10-25       Impact factor: 6.261

8.  Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in P-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cells.

Authors:  Soo-Jung Park; Khadijeh Bijangi-Vishehsaraei; Ahmad R Safa
Journal:  Int J Biochem Mol Biol       Date:  2010-07-18

9.  Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis.

Authors:  E Kerr; C Holohan; K M McLaughlin; J Majkut; S Dolan; K Redmond; J Riley; K McLaughlin; I Stasik; M Crudden; S Van Schaeybroeck; C Fenning; R O'Connor; P Kiely; M Sgobba; D Haigh; P G Johnston; D B Longley
Journal:  Cell Death Differ       Date:  2012-02-10       Impact factor: 15.828

10.  Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.

Authors:  T Trarbach; M Moehler; V Heinemann; C-H Köhne; M Przyborek; C Schulz; V Sneller; G Gallant; S Kanzler
Journal:  Br J Cancer       Date:  2010-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.